ATE395933T1 - Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus - Google Patents

Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus

Info

Publication number
ATE395933T1
ATE395933T1 AT98937834T AT98937834T ATE395933T1 AT E395933 T1 ATE395933 T1 AT E395933T1 AT 98937834 T AT98937834 T AT 98937834T AT 98937834 T AT98937834 T AT 98937834T AT E395933 T1 ATE395933 T1 AT E395933T1
Authority
AT
Austria
Prior art keywords
lupus erythematosus
systemic lupus
preventives
receptor antibodies
neutralizing anti
Prior art date
Application number
AT98937834T
Other languages
English (en)
Inventor
Masahiko Mihara
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16750530&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395933(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE395933T1 publication Critical patent/ATE395933T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT98937834T 1997-08-15 1998-08-14 Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus ATE395933T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22040097 1997-08-15

Publications (1)

Publication Number Publication Date
ATE395933T1 true ATE395933T1 (de) 2008-06-15

Family

ID=16750530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937834T ATE395933T1 (de) 1997-08-15 1998-08-14 Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus

Country Status (12)

Country Link
EP (2) EP1916020A3 (de)
JP (4) JP2009185073A (de)
KR (5) KR20040024561A (de)
AT (1) ATE395933T1 (de)
AU (1) AU747883B2 (de)
CA (1) CA2296322A1 (de)
CY (1) CY1108180T1 (de)
DE (1) DE69839517D1 (de)
DK (1) DK1004315T3 (de)
ES (1) ES2308809T3 (de)
PT (1) PT1004315E (de)
WO (1) WO1999008707A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
EP2374818B1 (de) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. Antikörper mit hoher Affinität für den menschlichen IL-6-Rezeptor
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN107551270A (zh) 2008-04-11 2018-01-09 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN103169966B (zh) * 2013-04-09 2015-04-01 中国人民解放军军事医学科学院基础医学研究所 一种治疗***性红斑狼疮的药物组合物
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US521628A (en) 1894-06-19 Housekeeping-cabinet
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0318554B2 (de) 1987-05-21 2005-01-12 Micromet AG Multifunktionelle proteine mit vorbestimmter zielsetzung
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
DE3835350A1 (de) 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
JP2803199B2 (ja) * 1989-08-07 1998-09-24 株式会社ニコン カメラの警告装置
JPH03155795A (ja) 1989-11-13 1991-07-03 Chuzo Kishimoto マウス・インターロイキン―６レセプター蛋白質
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
AU700819B2 (en) * 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
PL182089B1 (en) * 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
EP0811384B1 (de) * 1995-02-13 2006-06-21 Chugai Seiyaku Kabushiki Kaisha Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
US6060293A (en) 1995-03-31 2000-05-09 Prokyon Aps Resonance driven changes in chain molecule structure
EP1978033A3 (de) 1995-04-27 2008-12-24 Amgen Fremont Inc. Aus immunisiertem Xenomid abgeleitete menschliche Antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2005247872A (ja) * 1997-08-15 2005-09-15 Chugai Pharmaceut Co Ltd 抗ｉｌ−６レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および／または治療剤
JP3803199B2 (ja) * 1997-08-15 2006-08-02 中外製薬株式会社 抗ｉｌ−６レセプター抗体を有効成分として含有する全身性エリテマトーデスの予防および／または治療剤

Also Published As

Publication number Publication date
EP1004315B1 (de) 2008-05-21
DE69839517D1 (de) 2008-07-03
PT1004315E (pt) 2008-07-09
EP1916020A2 (de) 2008-04-30
KR20010022846A (ko) 2001-03-26
JP2009185073A (ja) 2009-08-20
AU8649498A (en) 1999-03-08
KR20080027967A (ko) 2008-03-28
AU747883B2 (en) 2002-05-30
EP1004315A1 (de) 2000-05-31
EP1916020A3 (de) 2008-07-02
CY1108180T1 (el) 2014-02-12
CA2296322A1 (en) 1999-02-25
WO1999008707A1 (fr) 1999-02-25
ES2308809T3 (es) 2008-12-01
KR20090068385A (ko) 2009-06-26
KR20100068498A (ko) 2010-06-23
EP1004315A4 (de) 2001-12-05
JP2015098491A (ja) 2015-05-28
JP2012214517A (ja) 2012-11-08
DK1004315T3 (da) 2008-07-21
KR20040024561A (ko) 2004-03-20
JP2017002087A (ja) 2017-01-05

Similar Documents

Publication Publication Date Title
ATE395933T1 (de) Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
ATE407696T1 (de) Vorbeugende- oder heilmittel zur behandlung von multipler sklerose, mit antagonistischen anti-il6-rezeptor antikörpern als wirkstoff
HK1059040A1 (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
IT1289728B1 (it) Dispositivo di impianto e corredo che lo comprende
HK1026377A1 (en) Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture.
DE3576910D1 (de) Klebstofflose gelenkpfannenkonstruktion fuer prothesen, sowie vorrichtung zur implantation.
LV12452A (lv) Aktivas vielas vaginala ievadisanas sistema
WO1997014806A3 (en) Delivery of biologically active polypeptides
NO981146L (no) Transcytotiske midler og forsterkere for medikamentleveranser
BR9610875A (pt) Modulares rxr seletivos - dimeros e processos para seu uso
ATE383875T1 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
DE69319824T2 (de) Vorrichtung zur Regulierung der Urin-Inkontinenz bei Frauen
AU2967692A (en) Improved composition and device for urinary protein assay and method of using the same
DE69329407D1 (de) Verfahren und Implantatvorrichtung für Langzeitwirkstoffabgabe
BR9811094A (pt) Agente terapêutico para tumores linfáticos
EP1041994A4 (de) Verwendung von parasitären biologischen wirkstoffen zur vorbeugung und kontrolle von autoimmunkrankheiten
ES2164434T3 (es) Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.
NL1000718A1 (nl) Inrichting voor het doelgericht nauwkeurig positioneren en stapelen van houders.
BR0211008A (pt) Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante
AU3552389A (en) An agent for desensitizing man and/or animals against an allergen
AU2001285835A1 (en) Device and method for raising an animal's hoof
IT1297168B1 (it) Dispositivo e metodo di preparazione per l'impianto di stents biforcati
ITMI930771V0 (it) Dispositivo di comando dell'accelleratore per autovetture destinate ad utenti privi dell'uso degli arti inferiori
ITMI930820A0 (it) Dispositivo di comando dell'acceleratore per autovetture per disabili
FR2724839B1 (fr) Dispositif de positionnement d'un implant en chirurgie reparatrice

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1004315

Country of ref document: EP